JP2021509900A5 - - Google Patents
Info
- Publication number
- JP2021509900A5 JP2021509900A5 JP2020537138A JP2020537138A JP2021509900A5 JP 2021509900 A5 JP2021509900 A5 JP 2021509900A5 JP 2020537138 A JP2020537138 A JP 2020537138A JP 2020537138 A JP2020537138 A JP 2020537138A JP 2021509900 A5 JP2021509900 A5 JP 2021509900A5
- Authority
- JP
- Japan
- Prior art keywords
- glycero
- biotin
- insulin
- dipalmitoyl
- phosphate
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614109P | 2018-01-05 | 2018-01-05 | |
| US62/614,109 | 2018-01-05 | ||
| PCT/US2019/012557 WO2019136386A1 (en) | 2018-01-05 | 2019-01-07 | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021509900A JP2021509900A (ja) | 2021-04-08 |
| JPWO2019136386A5 JPWO2019136386A5 (https=) | 2022-01-17 |
| JP2021509900A5 true JP2021509900A5 (https=) | 2022-01-17 |
| JP7517691B2 JP7517691B2 (ja) | 2024-07-17 |
Family
ID=67143976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537138A Active JP7517691B2 (ja) | 2018-01-05 | 2019-01-07 | 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200375913A1 (https=) |
| EP (1) | EP3735232A4 (https=) |
| JP (1) | JP7517691B2 (https=) |
| KR (1) | KR20200106912A (https=) |
| CN (1) | CN111712236A (https=) |
| AU (2) | AU2019205795A1 (https=) |
| BR (1) | BR112020013460A2 (https=) |
| CA (1) | CA3086771A1 (https=) |
| MX (1) | MX2020007067A (https=) |
| SG (1) | SG11202005920PA (https=) |
| WO (1) | WO2019136386A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| WO2018169954A1 (en) | 2017-03-13 | 2018-09-20 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
| US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
| WO2020210697A1 (en) * | 2019-04-12 | 2020-10-15 | Sdg, Inc. | Lipid-based nanoparticles and use of same in optimized insulin dosing regimens |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| EP1610758A4 (en) | 2003-03-19 | 2011-11-02 | Harry Hebblewhite | METHOD AND SYSTEM FOR DETERMINING INSULIN DOSAGE PLANES AND CARBOHYDRATE / INSULIN RELATIONSHIPS IN DIABETICS |
| US9872890B2 (en) * | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
| CN101237854B (zh) | 2005-05-23 | 2013-03-27 | Sdg公司 | 将胰岛素输送到哺乳动物的脂构建体 |
| US20110135725A1 (en) * | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US8846053B2 (en) * | 2008-09-26 | 2014-09-30 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| WO2010080976A1 (en) * | 2009-01-09 | 2010-07-15 | Sdg, Inc. (An Ohio Corporation) | Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments |
| AU2011265294B2 (en) * | 2010-06-10 | 2015-01-22 | Aquestive Therapeutics, Inc. | Nanoparticle film delivery systems |
| KR20140026396A (ko) * | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
| US20170000899A1 (en) * | 2013-11-26 | 2017-01-05 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
| US20180000953A1 (en) * | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2018169954A1 (en) * | 2017-03-13 | 2018-09-20 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
-
2019
- 2019-01-07 KR KR1020207021607A patent/KR20200106912A/ko not_active Ceased
- 2019-01-07 CA CA3086771A patent/CA3086771A1/en active Pending
- 2019-01-07 BR BR112020013460-0A patent/BR112020013460A2/pt unknown
- 2019-01-07 MX MX2020007067A patent/MX2020007067A/es unknown
- 2019-01-07 AU AU2019205795A patent/AU2019205795A1/en not_active Abandoned
- 2019-01-07 WO PCT/US2019/012557 patent/WO2019136386A1/en not_active Ceased
- 2019-01-07 US US16/959,617 patent/US20200375913A1/en not_active Abandoned
- 2019-01-07 SG SG11202005920PA patent/SG11202005920PA/en unknown
- 2019-01-07 EP EP19736007.6A patent/EP3735232A4/en active Pending
- 2019-01-07 JP JP2020537138A patent/JP7517691B2/ja active Active
- 2019-01-07 CN CN201980013264.1A patent/CN111712236A/zh active Pending
-
2023
- 2023-04-26 US US18/307,459 patent/US20240108585A1/en active Pending
-
2024
- 2024-11-28 AU AU2024266969A patent/AU2024266969A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023120371A5 (https=) | ||
| JP2025085727A5 (https=) | ||
| US20220160841A1 (en) | Glucose-responsive insulin delivery microneedle system | |
| JP2021509900A5 (https=) | ||
| Saito et al. | Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery | |
| JP2020510705A5 (https=) | ||
| JP7656353B2 (ja) | 向上した安定性を有する脂質ベースのナノ粒子 | |
| KR20060014027A (ko) | 지속성의 주사용 인슐린 조성물 및 그 제조방법 및사용방법 | |
| US20180271792A1 (en) | Oral delivery of physiologically active substances | |
| ES2965028T3 (es) | Producto liofilizado y suspensión de microvesículas llenas de gas | |
| EP2680822B1 (en) | Vesicle compositions | |
| Sun et al. | Development of functional or medical foods for oral administration of insulin for diabetes treatment: Gastroprotective edible microgels | |
| US12161749B2 (en) | Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery | |
| Oguma et al. | Effects of phospholipid type and particle size on lipid nanoparticle distribution in vivo and in pancreatic islets | |
| JP7517691B2 (ja) | 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物 | |
| Tariq et al. | Design, optimization & characterization of niosomal & polymeric nanoparticles | |
| JP2020500203A (ja) | サーファクタントタンパク質ｂと１つ以上の脂質とを含む粒子 | |
| Kunte et al. | Evaluation of transfection efficacy, biodistribution, and toxicity of branched amphiphilic peptide capsules (BAPCs) associated with mRNA | |
| JPWO2019136386A5 (https=) | ||
| JPWO2020210697A5 (https=) | ||
| JP2022526842A (ja) | 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 | |
| CN1631444A (zh) | 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法 | |
| JP2009507761A5 (https=) | ||
| KR20200067173A (ko) | 포도당-반응성 인슐린 전달을 위한 포도당 전달체 억제제-조절 인슐린 | |
| US9408917B2 (en) | Pharmaceutical composition |